Article
In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
Microbial drug resistance (Larchmont, N.Y.) - 1 Oct 2016
Roychoudhury Siddhartha, Makin Kelly, Twinem Tracy, Leunk Robert, Hsu Ming Chu
Abstract excerpt
Selection of resistant strains in Streptococcus pneumoniae was studied in vitro with nemonoxacin, a novel nonfluorinated quinolone (NFQ), in comparison with quinolone benchmarks, ciprofloxacin, garenoxacin, and gatifloxacin. In stepwise resistance selection studies, a 256-fold loss of potency was observed after three to four steps of exposure to ciprofloxacin or garenoxacin. In contrast, the loss of potency was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
